HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Stave, J. W. Articles by Morgan, D. O. Search for Related Content PubMed PubMed Citation Articles by Stave, J. W. Articles by Morgan, D. O. Agricola Articles by Stave, J. W. Articles by Morgan, D. O.

Analysis of Foot-and-Mouth Disease Virus Type O₁ Brugge Neutralization Epitopes Using Monoclonal Antibodies

United States Department of Agriculture, Plum Island Animal Disease Center, P.O. Box 848, Greenport, New York 11944, U.S.A.

Monoclonal antibodies (MAbs) were elicited with inactivated, purified foot-and-mouth disease virus (FMDV) type O₁ strain Brugge (140S) and with 12S protein subunits. Each MAb was tested for its capacity to bind to FMDV O₁ Brugge 140S virions, 12S subunits and purified VP1 by radioimmunoassay (RIA) and to neutralize viral infectivity in mouse protection assays. Those MAbs which reacted only with 12S subunits in RIA did not neutralize infectious virus. One MAb, 12FE9.2.1, reacted with 140S, 12S and purified VP1 of FMDV O₁ Brugge and neutralized infectious virus. Reactions with different biosynthetic FMDV type O₁ Campos VP1 polypeptides localized the binding site of 12FE9.2.1 between amino acid residues 135 and 172. Eight MAbs reacted with both 140S virions and 12S subunits and neutralized infectious virus. Monoclonal antibodies that reacted only with 12S protein subunits or with 140S, 12S and VP1 did not compete in RIA with 140S/12S-reactive neutralizing MAbs for 12S binding sites. The ability of 140S/12S-reactive MAbs to compete for the 12S binding site defined by MAb 10GA4.2.2 was directly related to their capacity to neutralize infectious virus, suggesting that these MAbs were all affecting a single neutralization site. In mouse protection and plaque reduction neutralization assays, 10GA4.2.2 and 12FE9.2.1 were equally effective in neutralizing the homologous FMDV type O₁ Brugge, and in cross-neutralization assays both exhibited high titres against four additional strains of type O₁ FMDV.

Keywords: FMDV, neutralization epitopes, monoclonal antibodies

Received 31 December 1985; accepted 27 June 1986.

This article has been cited by other articles:

				M. E. Piccone, Y. Feng, A. C. Y. Chang, R. Mosseri, Q. Lu, G. F. Kutish, Z. Lu, T. G. Burrage, C. Gooch, D. L. Rock, et al. Identification of Cellular Genes Affecting the Infectivity of Foot-and-Mouth Disease Virus J. Virol., July 1, 2009; 83(13): 6681 - 6688. [Abstract] [Full Text] [PDF]

				V. O'Donnell, M. LaRocco, and B. Baxt Heparan Sulfate-Binding Foot-and-Mouth Disease Virus Enters Cells via Caveola-Mediated Endocytosis J. Virol., September 15, 2008; 82(18): 9075 - 9085. [Abstract] [Full Text] [PDF]

				V. O'Donnell, M. LaRocco, H. Duque, and B. Baxt Analysis of Foot-and-Mouth Disease Virus Internalization Events in Cultured Cells J. Virol., July 1, 2005; 79(13): 8506 - 8518. [Abstract] [Full Text] [PDF]